Please login to the form below

Not currently logged in
Email:
Password:

Novel muscle relaxant reverser wins US priority review status

The FDA assigns priority review status to US-based pharmaceutical company Schering-Plough's NDA for sugammadex

The FDA has assigned priority review status to US-based pharmaceutical company Schering-Plough's (S-P) New Drug Application (NDA) for sugammadex.

Sugammadex reverses the effects of US-marketed muscle relaxants, such as Zemuron (rocuronium) and vecuronium, which are used in general anaesthesia during surgical procedures.

If approved, sugammadex will be the first in a new class of drugs known as selective relaxant binding agents which encapsulate the muscle relaxant molecule and render it inactive.

S-P's CMO, Dr Robert Spiegel, said: "Sugammadex has the potential to change the way doctors practice anaesthesia as it will allow anaesthesiologists to rapidly and safely reverse both shallow and profound levels of muscle relaxation, which is not possible with current reversal agents."

S-P acquired sugammadex through its acquisition of Organon BioSciences on 19 November 2007.

3rd January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics